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Abstract
Fanconi anemia (FA) is a rare genomic instability syndrome. Disease-causing are biallelic mutations in any one of at least 15
genes encoding members of the FA/BRCA pathway of DNA-interstrand crosslink repair. Patients are diagnosed based upon
phenotypical manifestationsand the diagnosis of FA is confirmed by the hypersensitivity of cells to DNA interstrand
crosslinking agents. Customary molecular diagnostics has become increasingly cumbersome, time-consuming and
expensive the more FA genes have been identified. We performed Whole Exome Sequencing (WES) in four FA patients in
order to investigate the potential of this method for FA genotyping. In search of an optimal WES methodology we explored
different enrichment and sequencing techniques. In each case we were able to identify the pathogenic mutations so that
WES provided both, complementation group assignment and mutation detection in a single approach. The mutations
included homozygous and heterozygous single base pair substitutions and a two-base-pair duplication in FANCJ, -D1, or -
D2. Different WES strategies had no critical influence on the individual outcome. However, database errors and in particular
pseudogenes impose obstacles that may prevent correct data perception and interpretation, and thus cause pitfalls. With
these difficulties in mind, our results show that WES is a valuable tool for the molecular diagnosis of FA and a sufficiently
safe technique, capable of engaging increasingly in competition with classical genetic approaches.
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Introduction
Fanconi anemia (FA) is an autosomal or X-chromosomal
recessive disorder characterized by variable yet typical develop-
mental malformations, bone marrow failure and predisposition to
leukemia and solid tumors. As much as 15 genes define
corresponding complementation groups designated as FA-A, -B,
-C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M, -N, -O and -P. Biallelic or
in the case of FA-B hemizygous mutations in any one of the
underlying genes lead to FA, while monoallelic mutations in
FANCD1 (BRCA2), FANCJ (BRIP1), FANCN (PALB2) or FANCO
(RAD51C) increase the risk of carriers for developing breast and
ovarian cancer [1]. FA patients commonly suffer from physical
abnormalities like short stature, abnormal skin pigmentation,
radial ray defects and malformations of the ears, eyes and inner
organs. More than 80% of FA patients develop progressive bone
marrow failure which makes pancytopenia a highly suggestive
clinical feature [2–4]. In addition, FA patients show not only
greatly elevated frequencies of myelodysplastic syndrome and
acute myeloid leukemia in childhood, but there is also markedly
increased prevalence of non-hematologic malignancies. They
experience an up to 700-fold higher risk of squamous cell
carcinomas especially of the head and neck or anogenital region
[3,5]. Other solid tumors are less frequent among FA patients but
a variety of them are still extraordinarily common compared to the
general population [5]. The reason for the overall increased cancer
risk may be due to the DNA repair defect that characterizes the
cellular phenotype [6]. FA cells show elevated rates of chromo-
somal breakage and typical radial rearrangement figures. These
features occur spontaneously but are exaggerated following
exposure of cultured cells to DNA crosslinking agents such as
diepoxybutane (DEB) or mitomycin C (MMC) [7–9]. Since this
hypersensitivity is typical for FA cells, chromosomal breakage
analysis is used as a diagnostic tool. Alternatively, cell cycle studies
or cellular survival assays using flow cytometric methods are
utilized for diagnosis because FA cells are hindered to pass the G2
checkpoint control, accumulate in G2 phase of the cell cycle and
show increased death rates after DNA damage induction [10,11].
On the molecular level diagnosis is more complicated. Even
though about 60% of FA patients carry mutations in FANCA [3],
14 other FA and several associated genes remain that may contain
disease-causing defects. While there is so far no cure for FA,
knowledge of the individual complementation group and the
specific mutations of patients may be important for differential,
prenatal or preimplantation diagnosis, prognosis or upcoming
gene therapy trials. Biallelic mutations of FANCD1, for example,
are associated with early-onset acute myelogenous leukemia and
blastomas [12,13]. Subtyping of FA patients can be performed by
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cell fusion experiments, retroviral complementation analysis or in
some cases by Western blotting, but the specific mutations have to
be analyzed by Sanger sequencing. Because of the high number of
FA and FA-associated genes and because some of these genes have
more than 40 exons, DNA sequencing by Sanger technique is
becoming increasingly tedious, time-consuming and costly.
Recently, an efficient and reliable technique, Next Generation
Sequencing (NGS), emerged to improve and accelerate conven-
tional methods of molecular diagnostics. In the present study we
demonstrate the versatility of Whole Exome Sequencing (WES) in
four independent projects. The four patients involved had
previously been confirmed to be afflicted with FA by non-
molecular procedures but were not assigned to any complemen-
tation group and thus lacking accountable mutations. Using WES
we genotyped each patient by the identification of their disease-
causing mutations in one of three different FA genes. Thus we
consider WES an efficient tool to compete with traditional
approaches for the molecular diagnosis of FA.
Materials and Methods
Study design
The study scope, patient information and consent form were
approved by the Ethical Review Committee of the Medical
Faculty of the University of Wuerzburg.
Figure 1. Cell cycle analysis. (A) Graphic presentation of the results of flow cytometric cell cycle analysis. Peripheral blood lymphocytes were
exposed to MMC. The ratio ‘‘sum of all G2 phases vs. growth fraction’’ was calculated from individual cultures and plotted against the G0/G1 phase
compartment. Cells from patient 1 and the siblings 2–1, 2–2 and 2–3 show highgG2/GF ratios (blue squares) similar to those from other persons with
FA (red diamonds), but were distinct of normal controls (green dots). (B) Flow histograms of fibroblast cultures from patients 3 and 4 show increased
G2 arrest after exposure to MMC, in contrast to a control cell line (arrows).
doi:10.1371/journal.pone.0052648.g001
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Cell cycle analysis
For confirmation or exclusion of FA we used flow cytometric
cell cycle analysis as described earlier [11,14].
DNA sample preparation
Genomic DNA was isolated from patient-derived fibroblasts
(patients 1, 3 and 4) using the GeneJetTM Genomic DNA
Purification Kit (Fermentas, patients 1 and 3) or the QIAamp
DNA isolation kit (Qiagen, patient 4) following the manufacturer’s
instructions. For isolation of gDNA from peripheral blood of
patient 2–1, his siblings 2–2 and 2–3 and their parents we used a
salting-out technique.
Whole Exome Sequencing
Enrichment and sequencing of the exomes of projects 1 to 3
were commissioned to different service providers on an exclusively
commercial basis. Sample 1 was enriched by means of the
NimbleGen SeqCap EZ Human Exome Library v2.0 and sequenced on an
Illumina HiSeq2000. For sample 2 the Agilent SureSelect Human All
Exon 38 Mb Kit (hg18) was used together with the SOLiD
sequencing technology by Applied Biosystems. In project 3 WES
was performed with SOLiD4 technology after enrichment using the
Agilent SureSelect Human All Exon 50 Mb Kit (hg19). Raw data from
Illumina sequencing were provided in fq format. SOLiD raw data
were provided in csfasta format along with qual files containing
corresponding quality information. For project 4 we used the
SureSelect Human All Exon Kit (Agilent) targeting approximately
38 Mb, following the manufacturer’s instructions. The enriched
sample was sequenced on one lane of the Illumina GAIIx instrument
using a paired-end sequencing protocol, which is available upon
request.
Data analysis
Analysis of the WES data of projects 1 to 3 was performed using
the alignment and analysis software NextGENeTM v2.18 by
Softgenetics. The raw data were filtered for low quality reads before
alignment. Based on the enrichment kits being used, reads that
passed the quality filter were aligned to the whole human genome
hg18 in project 2 and hg19 in projects 1 and 3. The average
exome coverage was determined using a complete list of human
exons generated by the UCSC Table Browser. The same procedure
was performed for FA gene coverage. The following analytical
steps were performed only with reads that matched exonic regions
including exon-intron-boundaries. SNP and insertion/deletion
(indels) analysis was done by different filtering steps depending on
whether consanguinity was suspected or not. In patient 2–1 of
consanguineous descent only homo-/hemizygous variants were
taken into account. In patients 1 and 3 with non-consanguineous
background genes with at least two heterozygous changes in the
DNA sequence were considered to be most likely disease-causing,
even though homozygous variants were not completely with-
drawn.
For sample 4 we used a data analysis pipeline for the evaluation
of single nucleotide variants and small indels, which was
comprised of tools freely available on the web. The paired-end
reads were mapped by the Burrows-Wheeler Aligner (BWA) [15]
to the reference genome built according to NCBI hg19.
Subsequently, SNPs and small indels were called using Samtools
[16] and Varscan [17]. The resulting list of variants was annotated
with Annovar [18] that summons and utilizes information from
external databases to assess implications and consequences of a
given sequence alteration, such as an ensuing amino acid change,
location within a canonical splice site, and information from
Table 1. Summary of statistical data from four independent WES projects.
Project 1 Project 2 Project 3 Project 4
Total read number 33,661,920 121,791,357 152,961,886 27,371,419
Average read lenght 86bp 45bp 40bp 72bp
Reads passing QC 32,251,042 82,558,019 117,526,556 27,371,419
Reads on target (whole exome) 29,837,615 (93%) 67,361,646 (82%) 83,597,787 (71%) 20,707,708 (76%)
Reads on target (FA genes) 17,518 93,806 76,257 31,925
Average exome coverage 22x 77x 71x 36x
Average coverage of FA genes 21x 56x 53x 31x
Total number of variants 20,065 13,466 14,978 18,885
Known SNPs/MNPs 15,213 9,846 13,563 15,469
UV in cs 4,652 3,567 1,386 3,281
UV at ess 200 46 29 136
Homozygous UV (cs+ess) 107 201 44 30
Heterozygous UV (cs+ess) 4,745 3,419 1,371 3,387
Silent UV (cs) 1,012 het 73 hom 286 het 884
Missense UV (cs) 2,736 het 102 hom 920 het 2,289
Nonsense UV (cs) 113 het 1 hom 44 het 23
Unknown InDels (cs+ess) 766 het 24 hom 101 het 77
Multiply heterozygous mutated genes 683 - 207 411
Homozygous mutated genes - 102 - -
QC, quality control; UV, unknown variants; cs, coding sequence; ess, essential splice sites; SNP, single nucleotide polymorphism; MNP, multiple nucleotide
polymorphism.
The initial number of genes with homozygous or double heterozygous mutations was counted without filtering for low mutation scores or benign sequence changes.
doi:10.1371/journal.pone.0052648.t001
Genotyping FA Patients by Whole Exome Sequencing
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e52648
dbSNP along with the SNP frequency if available. Finally, a
manual filtering step was carried out to prioritize relevant
mutations.
Filtering strategy
Holding for all samples, the variant detection frequency was set
at a minimum of 20% of the reads covering any aberration. A
minimum coverage by 10 reads was set as threshold for any
variant to be considered a real mutation. In each case all variants
listed in the most recent version of the NCBI (National Center for
Biotechnology Information) dbSNP database were excluded as
well as silent mutations. Low frequency frameshift and truncating
mutations in any FA gene were considered pathogenic. Unreport-
ed non-synonymous amino acid variants were analyzed in silico by
Align-GVGD (data not shown), MutationTaster (http://www.
mutationtaster.org), Polyphen-2 (http://genetics.bwh.harvard.
edu/pph2) and SIFT (http://sift.jcvi.org) to assess any potentially
damaging effect. Variants passing these filtering steps were
considered to be most likely disease-causing and forwarded to
validation process by Sanger sequencing and other techniques.
Figure 2. Genotyping of patient 1. (A) The heterozygous FANCD2 splice site mutation c.3888+2T.G in patient 1. The upper panel demonstrates
mutation calling in NGS data format. The lower panel shows an electropherogram of Sanger cDNA sequencing depicting heterozygous skipping of
exon 39. (B) The heterozygous FANCD2missense mutation c.2204G.A. The upper panel demonstrates the substitution in NGS data format, while the
lower panel shows the confirmation by Sanger sequencing of gDNA. (C) An immunoblot shows very faint FANCD2-S and -L bands after exposure of
fibroblasts from patients 1 to MMC (lane 3). This was similar to other FA-D2 patients (example on lane 2) but contrasted markedly to normal controls
(example on lane 1). RAD50 was used as loading control.
doi:10.1371/journal.pone.0052648.g002
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Figure 3. Genotyping of patient 2. (A) Homozygous mutation call c.1878A.T in FANCJ detected in NGS data of patient 2–1. (B) Autozygosity
mapping with SNP data of the family of project 2. The figure schematically presents chromosome 17 (positions in Mb) of each family member.
Heterozygous SNP calls are displayed in yellow, homozygous calls in black. The three affected siblings share a homozygous region between 53.3 Mb
Genotyping FA Patients by Whole Exome Sequencing
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Sanger sequencing
Potential mutations were verified by Sanger sequencing
generally using an Applied Biosystems 3130xl instrument. Primer
sequences and PCR conditions are available upon request.
Immunoblotting
FANCD2 expression analysis was performed with whole protein
extracts isolated from patient-derived fibroblasts. Cell lines were
treated with hydroxyurea or MMC before analysis. We used
primary antibodies including mouse monoclonal anti-FANCD2
(sc20022, Santa Cruz Biotechnology), mouse monoclonal anti-
RAD50 (GTX70228, GeneTex), rabbit polyclonal anti-RAD51
(ab63801, Abcam), rabbit polyclonal anti-FANCJ (NB 100-416A,
Novus) and mouse monoclonal anti-Vinculin (sc-25336, Santa
Cruz Biotechnology). Secondary antibodies included Alexa Fluor
594 goat anti-rabbit IgG (H+L) (A11012, Invitrogen), Goat pAb to
rabbit IgG (HRP) (ab97200, Abcam), Donkey pAb to mouse IgG
(HRP) (ab98665, Abcam).
Autozygosity mapping
Autozygosity mapping was performed with SNP data generated
with the Illumina SNP array HumanHap300v2. Genotypes were
analyzed using AutoSNPa software [19].
Results
Confirmation of the FA diagnosis
In each project the clinical diagnosis was confirmed by flow-
cytometric cell cycle analysis. In patients 1 and 2 FA was evident
from studies of peripheral blood lymphocyte cultures. After 72 h
incubation with 10 ng/ml MMC the ratio ‘‘sum of all G2 phases
vs. growth fraction’’ was above 0.4 which is characteristic of FA
patients (Fig. 1A) [20]. Patients 3 and 4 showed distinct cell
accumulations in the G2 phase (.20%) in fibroblast cultures
and 68.8 Mb. (C) Confirmation of homozygosity of the mutation in patient 2–1 and heterozygosity in his parents by Sanger sequencing
electropherograms, consistent with Mendelian segregation.
doi:10.1371/journal.pone.0052648.g003
Figure 4. Genotyping of patient 3. (A) NGS data in the upper panel show the insertion c.7890_7891insAA in FANCD1 detected in patient 3. The
electropherogram in the lower panel demonstrates corresponding validation by Sanger sequencing. (B) The upper panel misleadingly displays the
single-bp substitution c.7795G.A in the NGS data of patient 3 as a SNP, highlighted in pink. Confirmation by Sanger sequencing is shown below.
doi:10.1371/journal.pone.0052648.g004
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exposed to 12 ng/ml MMC for 48 h, likewise consistent with
other FA patients (Fig. 1B).
Mutation detection by WES and validating experiments
Statistical data of each WES project are summarized in Table 1
and Table S2. The exome was covered on average between 22x
and 77x. The FA and FA-associated genes with homozygous or at
least two potentially heterozygous mutations were first assessed.
Assignment of the mutations to different alleles and screening for
their pathogenicity revealed the following results.
Project 1. We employed 3 mg gDNA isolated from cultured
fibroblasts of patient 1 to enrich the whole exome. WES revealed
Figure 5. Genotyping of patient 4. (A) Displayed is the FANCD2 mutation c.1370T.C in patient 4 in NGS data as well as validated by Sanger
sequencing. (B) The upper panel shows NGS data with low coverage of FANCD2 exon 5 containing the substitution c.376A.G. The electropherogram
in the lower panel depicts validation by Sanger sequencing. (C) Hydroxyurea (HU) treated (+) and untreated (2) fibroblasts of patient 4 show very low
levels of both the S and L species of residual FANCD2 protein. Vinculin was used as loading control.
doi:10.1371/journal.pone.0052648.g005
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two heterozygous mutations with a score $10 (probability 1:100
for being false positive) exclusively in FANCD2. They included the
single-base substitution c.2314G.T, resulting in a premature stop
codon at amino acid position p.772, and the canonical splice site
change c.3888+2T.G in exon 38. Sanger sequencing confirmed
the splice site alteration in gDNA and showed an in frame skipping
of exon 39 at the cDNA level (Fig. 2A). Because of the pseudogene
FANCD2-P2, containing an incomplete copy of the active gene
region [21], validation of the nonsense mutation by Sanger
sequencing was performed on long range PCR product (exon 22 to
exon 26). Re-sequencing of this super-amplicon did not confirm
the substitution c.2314G.T (Fig. S1A). Thus we concluded that
this variant had occurred in the pseudogene and therefore could
not be causative of FA in that patient. By decreasing the filter
settings we additionally detected the missense substitution
c.2204G.A in exon 24 resulting in the amino acid change
p.R735Q. Even though this base is alsopresent in the pseudogene
sequence, its assessment by gene-specific super-amplification
rendered it an authentic FANCD2 mutation (Fig. 2B). We
confirmed the maternal segregation of p.R735Q, whereas the
splice site change was not present in maternal gDNA and may
have occurred de novo or was, more likely, inherited from the
father, of whom no material was available. Finally, decreased
abundance of FANCD2 protein in the patient’s cells confirmed
our DNA sequencing results (Fig. 2C).
Project 2. Parallel to WES we performed a genome-wide
SNP study in patient 2–1, his two affected siblings (2–2, 2–3) and
their parents. Autozygosity mapping using these data revealed a
large homozygous region on chromosome 17 (Fig. 3A). The whole
exome was enriched from 3 mg gDNA, isolated from peripheral
blood of patient 2–1. Analysis of the color-spaced SOLiD4
sequencing data revealed the homozygous single base substitution
c.1878A.T in exon 13 of FANCJ (Fig. 3B) compatible with the
outcome of the disease gene mapping. This point mutation results
in the amino acid change p.E626D (Fig. 3B) that is predicted to be
pathogenic (Table S1). Sanger sequencing confirmed the homo-
zygous mutation of the patient (Fig. 3C) and his siblings (data not
shown). These results and the heterozygous detection of the
mutation in both parents (Fig. 3C) were consistent with Mendelian
segregation. Additionally we could detect reduced FANCJ protein
levels by Western blot analysis of whole protein extracts from
patient derived-cell lines (data not shown).
Project 3. 3 mg gDNA of patient 3 were isolated from
fibroblasts. Initial analysis of the WES data failed to show FA or
FA-associated genes with biallelic mutations. Re-examination of
all unknown variants and listed SNPs resulted in the identification
of a 2-bp insertion c.7890_7891dupAA in exon 17 of BRCA2/
FANCD1 (Fig. 4A) with the effect p.L2631Nfs16X. Three
additional variants were found in the same gene, of which only
c.7795G.A was predicted to be pathogenic (Fig. 4B, Table S1).
The SNP rs80359682 listed at this position is a deletion of three
bases (c.7795_7797delGAA) in exon 16, which is of unknown
pathogenicity, whereas our detected single-bp substitution results
in the probably damaging missense mutation p.E2599K. We
confirmed both mutations of patient 3 by Sanger sequencing, even
though the allele carrying the insertion was detectable only at a
very low level (Fig. 4A). In accordance with those results we
detected proficient FANCD2 monoubiquitination and impaired
RAD51 foci formation in the patient derived fibroblastic cell line
(data not shown).
Project 4. In contrast to projects 1 to 3, where data have been
analyzed by means of the alignment and analysis software
NextGENeTM v2.18 by Softgenetics, we used for project 4 an in-
house variation detection pipeline to score sequence variants [21].
We focused on rare variants within the coding and splice site
regions of all known FA genes. Only one already reported
heterozygous base substitution was detected in FANCD2 exon 16,
c.1370T.C (p.L457P), which had previously been recognized to
be pathogenic [22]. Initially we failed to detect a second mutation
in FANCD2. After visual inspection of the mapped reads in the
IGV browser, FANCD2 exon 5 was shown to be covered by a
single read. Therefore, the data appeared unreliable for mutation
detection. Subsequent Sanger sequencing of that exon demon-
strated a c.376A.G base substitution resulting in another
missense mutation p.S126G, that had previously been shown to
be pathogenic and affects splicing [23] (Fig. 5A). Western blotting
revealed distinct deficiency of the FANCD2 protein (Fig. 5B).
Discussion
The present study proposes the application of WES for the
molecular diagnosis of FA. Major concerns with WES are ethical
issues, less its performance. Potentially, WES data could be used to
analyze any gene, or even all genes, for any purpose. In our
projects the patients had given informed consent for FA
diagnostics. We addressed and resolved the discrepancy to WES
in the way that we used the whole body of data only for quality
control, statistical analyses, and to apply general filtering settings.
For mutation screening we solely regarded FA and FA-associated
genes.
We performed four independent sequencing projects with
disparate exome enrichment and sequencing technologies. Al-
though the performances differed slightly, we were able to identify
the disease causing mutations in all index patients. Except for the
mutations in patient 4, all of the detected pathogenic variants had
not yet been listed in the Fanconi Anemia Mutation Database (http://
www.rockefeller.edu/fanconi/) such that we consider the identi-
fication of missense, nonsense and splice site mutations as well as a
2-bp insertion in FANCD1, FANCD2 and FANCJ by WES a
challenging task and major accomplishment. The successful
outcome led us to conclude that WES generally is a reliable tool
for the molecular diagnosis of FA. It also proved to be efficient in
time and adequate in expense. Including sample quality control,
target enrichment, sequencing and basic bioinformatics each of
our projects was brought to completion within two to three
months. Alignment and mutation calling afforded another few
days, followed by validation processes. The cost of each of the four
projects was highly variable and ranged from 800$ to 4500$, but
decreased in tendency over time. Sanger sequencing of all FA
genes would have exceeded the projects’ current term and cost
several times. Sanger sequencing of the 43 FANCA exons only
would be comparable to the price of exome sequencing but would
fail to detect the mutation in more than 40% of cases. Enrichment
of the FA gene regions followed by NGS would be an effective
alternative, because it could increase the locus-specific coverage
and decrease cost and sequencing time. Although this approach
has been published recently [21], so far this application is not
commercially available for the FA genes. In some instances WES
holds some advantages compared to a target enrichment
approach, because there are still FA patients who cannot be
assigned to any of the reported complementation groups. In
agreement with the patient WES data can be used for further
screenings not only including FA-associated genes such as
FAAP100, but also of other candidate genes. An additional
agreement between patient and the diagnostic lab addressing this
issue is required.
In all presented cases we found point mutations or small
insertions to be disease-causing. Therefore we can safely assume
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that those patients do not carry additional large insertions or
deletions, which would have been difficult to identify by WES. In
the case of large and complex variations this technical drawback
can, however, be avoided if WES is combined with MLPA or
microarray techniques. Additionally a recent report by Ameziane
et al. (2012) detected large deletions after NGS of enriched FA
gene regions by evaluating the Log2 ratio of the local read depth
divided by a read depth reference [21]. None of the FA patients in
our four projects had mosaicism in the hematopoietic system as
shown by diagnostic procedures preceding WES. If there was
indication for such a situation it would have been appropriate to
use fibroblast DNA for WES. Deep intronic mutations, which
could affect splicing, might be the only kind of sequence changes
that are not detectable by WES. However those mutations are rare
in FA and would anyway be difficult to identify by classical
approaches. Our study also raised technical issues and revealed
methodical difficulties that should be addressed. For each project
we analyzed the exome coverage and in particular the coverage of
the FA genes (Table 1). Even though the average exome coverage
in the SureSelect enrichment projects clearly exceeded the coverage
in the NimbleGen project, we found coverage of the FA gene regions
in the latter to be more consistent and complete (Table S2). A
similar observation was reported by Clark et al. (2011) for the
whole exome in general. Most of the entirely unsequenced exons
in our study had a high GC or high AT content leading to the
conclusion that excess GC content is still a limiting factor for
efficient hybridization and amplification during target enrichment
[24]. In project 4 initially only one pathogenic mutation was
detected, while the other mutation was missed because of
insufficient coverage. In this case the GC and AT content of
FANCD2 exon 5, where the second mutation later was identified, is
balanced with 44% and 56%, but probably the high AT content of
the adjacent intron regions that were included in enrichment may
explain the low coverage. Nevertheless, the identification of the
first mutation led to close examination of that gene and subsequent
identification of the second mutation. On the other hand it is a
rare but recurrent experience that a single heterozygous mutation
in one FA gene may accompany compound heterozygous, disease-
causing mutations in another FA gene.
We observed a lower rate of sequencing errors in SOLiD data.
The two-base-encoding technology leads to lower rates of false
positive or false negative base calls and facilitates the discrimina-
tion of sequencing errors from authentic mutations [25,26].
Incomplete or even contradictory gene databases can complicate
the validation process and can cause confusion by wrong and
incomplete or misleading mutation calling. In project 3 we
experienced a problem even with SNP databases. A truly
pathogenic mutation was designated as a SNP because there was
a known polymorphism that included the mutated base pair. To
avoid such pitfalls as far as possible and because mutation
screening becomes easier the more polymorphisms are excluded,
we recommend using always the latest version of the dbSNP
database in combination with minor allele frequencies and
information from other sources such as the 1000 Genomes project.
Another issue to consider during in silico pathogenicity
assessment is the choice of mutation prediction software. For the
mutations described in this study we compared the performance of
three different mutation prediction tools (SIFT, PolyPhen-2 and
MutationTaster). While SIFT and Polyphen-2 often failed to ascertain
the pathogenic effect of the mutations, MutationTaster generally was
able to provide a reliable prognosis for all genes and every type of
mutations.
Finally, in this and other NGS studies we noticed that the
existence of pseudogene sequences can complicate the detection of
genuine mutations residing in functional genes and thus may result
in false positives. In project 1 re-sequencing showed that the
c.2314G.T mutation call in FANCD2 was due to incorrect
mapping of the variant containing reads, which should have
mapped to the pseudogene, FANCD2-P2. The missense mutation
c.2204G.A likewise represented FANCD2-P2 pseudogene se-
quence. In this case it proved to be a true FANCD2 mutation at
the same time. In that same exon we identified two more base
substitutions representing pseudogene sequence but the correspond-
ing reads were misleadingly mapped to FANCD2. Only gene-specific
re-sequencing resolved the correct sequence (data not shown). We
recognized this problem not only in FA genes. For example, another
project had revealed a hemizygous deletion including the CDC27
locus, but WES unexpectedly showed heterozygous base variants of
that gene. On closer inspection we found three related pseudogenes,
containing the complete cDNA sequence of CDC27 from exon 3 to
14. This led us to re-check the putative gene variants by Sanger
sequencing. All of them turned out to be false positives attributable
to pseudogene sequences (data not shown). We suggest that this
problem may be due to the short read length produced by SOLiD
and Illumina NGS and ambiguous mapping during alignment with
the genome. Pseudogenes are characterized by high sequence
similarity with their corresponding functional genes and therefore
ambivalent mapping in the analysis of NGS data cannot always be
avoided. In terms of FA genes, special attention needs to be paid to
FANCD2 for which only FANCD2-P1 LOC100421239 is listed in the
NCBI database but not the other reported pseudogene, FANCD2-P2
[22]. For FANCL and the FA-associated gene MHF1 at least partial
copies have been disclosed.
Notwithstanding the challenges with WES data analysis, we
would recommend it as a valuable tool for FA genotyping. In our
opinion, WES, if carefully applied, is able to compete with classical
molecular approaches in diagnostics and research not only for FA
but generally for other disorders with locus heterogeneity.
Supporting Information
Figure S1 Validation by Sanger technique. (A) Sanger
sequencing of cDNA revealed a false positive result of c.2314
G.T in FANCD2 being a mutation of patient 1 due to interference
with the pseudogene FANCD2-P2. (B) Confirmation of Mendelian
segregation of c.2204 G.A and c.3888+2 T.G. The missense
mutation is inherited from the mother. The healthy sister is a
heterozygous mutation carrier. The canonical splice site change
must have occurred de novo or been inherited from the father whose
DNA was not available. It was not detectable in other family
members.
(DOCX)
Table S1 Predicted effect of the mutations detected in
FANCD1, FANCD2 and FANCJ.
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